Do analysts recommend JF or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score J And Friends 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, JF or ENTO?

J And Friends has higher revenue and earnings than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio J And Friends $1.60M 10.96 -$1.32M N/A N/A Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A

Is JF or ENTO more profitable?

J And Friends' return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets J And Friends N/A N/A N/A Entero Therapeutics N/A -461.02% -14.72%

Do analysts rate ENTO or TBMC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trailblazer Merger Corporation I 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ENTO or TBMC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A Trailblazer Merger Corporation I N/A N/A -$8.29M N/A N/A

Is ENTO or TBMC more profitable?

Trailblazer Merger Corporation I's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% Trailblazer Merger Corporation I N/A N/A -37.04%

Do analysts prefer IDAI or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score T Stamp 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PT or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pintec Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, PT or ENTO?

Pintec Technology has higher revenue and earnings than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pintec Technology $35.55M 0.43 -$2.12M N/A N/A Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A

Is PT or ENTO more profitable?

Pintec Technology's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pintec Technology N/A N/A N/A Entero Therapeutics N/A -461.02% -14.72%

Do analysts prefer SMSI or ENTO?

Smith Micro Software currently has a consensus price target of $12.50, suggesting a potential upside of 362.96%. Given Smith Micro Software's stronger consensus rating and higher possible upside, equities analysts clearly believe Smith Micro Software is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith Micro Software 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Entero Therapeutics (ENTO) Competitors

$3.86 -0.03 (-0.77%)

As of 09/23/2026

Compare

ENTO vs. JF, TBMC, IDAI, PT, and SMSI

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include J And Friends (JF), Trailblazer Merger Corporation I (TBMC), T Stamp (IDAI), Pintec Technology (PT), and Smith Micro Software (SMSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to J And Friends?

J And Friends (NASDAQ:JF) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

J And Friends' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
J And Friends	N/A	N/A	N/A
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
J And Friends	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, J And Friends had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for J And Friends and 0 mentions for Entero Therapeutics. J And Friends' average media sentiment score of 1.86 beat Entero Therapeutics' score of 0.75 indicating that J And Friends is being referred to more favorably in the media.

Company	Overall Sentiment
J And Friends	Very Positive
Entero Therapeutics	Positive

6.6% of J And Friends shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 4.1% of J And Friends shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

J And Friends has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

J And Friends has higher revenue and earnings than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
J And Friends	$1.60M	10.96	-$1.32M	N/A	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Summary

J And Friends beats Entero Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Entero Therapeutics compare to Trailblazer Merger Corporation I?

Entero Therapeutics (NASDAQ:ENTO) and Trailblazer Merger Corporation I (NASDAQ:TBMC) are both small-cap technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Trailblazer Merger Corporation I	N/A	N/A	-$8.29M	N/A	N/A

Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Trailblazer Merger Corporation I has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Trailblazer Merger Corporation I's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Trailblazer Merger Corporation I	N/A	N/A	-37.04%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trailblazer Merger Corporation I	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Entero Therapeutics' average media sentiment score of 0.75 beat Trailblazer Merger Corporation I's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Trailblazer Merger Corporation I	Neutral

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 77.1% of Trailblazer Merger Corporation I shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 86.4% of Trailblazer Merger Corporation I shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Trailblazer Merger Corporation I beats Entero Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Entero Therapeutics compare to T Stamp?

T Stamp (NASDAQ:IDAI) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, T Stamp had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for T Stamp and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.75 beat T Stamp's score of 0.26 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
T Stamp	Neutral
Entero Therapeutics	Positive

16.3% of T Stamp shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 4.5% of T Stamp shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

T Stamp has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
T Stamp	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

T Stamp has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than T Stamp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
T Stamp	$3.14M	5.51	-$8.32M	-$2.01	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Entero Therapeutics has a net margin of 0.00% compared to T Stamp's net margin of -272.78%. T Stamp's return on equity of -137.70% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
T Stamp	-272.78%	-137.70%	-84.06%
Entero Therapeutics	N/A	-461.02%	-14.72%

Summary

T Stamp beats Entero Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Pintec Technology?

Pintec Technology (NASDAQ:PT) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Pintec Technology's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pintec Technology	N/A	N/A	N/A
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pintec Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Entero Therapeutics' average media sentiment score of 0.75 beat Pintec Technology's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pintec Technology	Neutral
Entero Therapeutics	Positive

Pintec Technology has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Pintec Technology has higher revenue and earnings than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pintec Technology	$35.55M	0.43	-$2.12M	N/A	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

6.6% of Pintec Technology shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 4.1% of Pintec Technology shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pintec Technology beats Entero Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Entero Therapeutics compare to Smith Micro Software?

Smith Micro Software (NASDAQ:SMSI) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Entero Therapeutics has lower revenue, but higher earnings than Smith Micro Software. Entero Therapeutics is trading at a lower price-to-earnings ratio than Smith Micro Software, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith Micro Software	$17.36M	0.87	-$29.33M	-$3.52	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Smith Micro Software currently has a consensus price target of $12.50, suggesting a potential upside of 362.96%. Given Smith Micro Software's stronger consensus rating and higher possible upside, equities analysts clearly believe Smith Micro Software is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith Micro Software	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Smith Micro Software has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

20.8% of Smith Micro Software shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 34.7% of Smith Micro Software shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Entero Therapeutics has a net margin of 0.00% compared to Smith Micro Software's net margin of -92.60%. Smith Micro Software's return on equity of -44.59% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith Micro Software	-92.60%	-44.59%	-31.78%
Entero Therapeutics	N/A	-461.02%	-14.72%

In the previous week, Smith Micro Software had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for Smith Micro Software and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.75 beat Smith Micro Software's score of 0.54 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith Micro Software	Positive
Entero Therapeutics	Positive

Summary

Smith Micro Software beats Entero Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTO vs. The Competition

Export

Metric	Entero Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$6.13M	$15.97B	$31.40B	$13.29B
Dividend Yield	N/A	3.42%	2.75%	12.57%
P/E Ratio	-2.28	142.56	79.00	25.76
Price / Sales	N/A	1,288.83	590.01	111.79
Price / Cash	N/A	47.54	49.70	52.76
Price / Book	-1.58	8.86	7.98	6.34
Net Income	-$18.06M	$434.54M	$702.99M	$360.00M
7 Day Performance	27.81%	0.95%	1.19%	-0.18%
1 Month Performance	5.75%	-2.44%	-1.77%	-4.09%
1 Year Performance	-18.05%	-0.28%	178.19%	5.97%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTO Entero Therapeutics	0.0486 of 5 stars	$3.86 -0.8%	N/A	-23.0%	$6.13M	N/A	N/A	9
JF J And Friends	0.1258 of 5 stars	$1.02 +2.4%	N/A	N/A	$18.78M	$1.60M	N/A	30	Positive News
TBMC Trailblazer Merger Corporation I	N/A	$7.33 flat	N/A	N/A	$17.96M	N/A	N/A	N/A
IDAI T Stamp	1.2746 of 5 stars	$2.94 +0.9%	$12.00 +308.9%	-8.1%	$16.55M	$3.44M	N/A	75	Short Interest Increase
PT Pintec Technology	N/A	$1.00 -1.0%	N/A	-2.2%	$15.85M	$35.55M	N/A	120	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (ENTO) Competitors

ENTO vs. JF, TBMC, IDAI, PT, and SMSI

How does Entero Therapeutics compare to J And Friends?

Summary

How does Entero Therapeutics compare to Trailblazer Merger Corporation I?

Summary

How does Entero Therapeutics compare to T Stamp?

Summary

How does Entero Therapeutics compare to Pintec Technology?

Summary

How does Entero Therapeutics compare to Smith Micro Software?

Summary

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (ENTO) Competitors

ENTO vs. JF, TBMC, IDAI, PT, and SMSI

How does Entero Therapeutics compare to J And Friends?

Is JF or ENTO more profitable?

Do analysts recommend JF or ENTO?

Does the media prefer JF or ENTO?

Do institutionals & insiders believe in JF or ENTO?

Which has more volatility and risk, JF or ENTO?

Which has better earnings and valuation, JF or ENTO?

Summary

How does Entero Therapeutics compare to Trailblazer Merger Corporation I?

Which has stronger valuation and earnings, ENTO or TBMC?

Which has more volatility and risk, ENTO or TBMC?

Is ENTO or TBMC more profitable?

Do analysts rate ENTO or TBMC?

Does the media refer more to ENTO or TBMC?

Do insiders and institutionals believe in ENTO or TBMC?

Summary

How does Entero Therapeutics compare to T Stamp?

Does the media favor IDAI or ENTO?

Do insiders & institutionals have more ownership in IDAI or ENTO?

Which has more volatility and risk, IDAI or ENTO?

Do analysts prefer IDAI or ENTO?

Which has better earnings & valuation, IDAI or ENTO?

Is IDAI or ENTO more profitable?

Summary

How does Entero Therapeutics compare to Pintec Technology?

Is PT or ENTO more profitable?

Do analysts prefer PT or ENTO?

Does the media prefer PT or ENTO?

Which has more risk & volatility, PT or ENTO?

Which has stronger earnings and valuation, PT or ENTO?

Do insiders and institutionals hold more shares of PT or ENTO?

Summary

How does Entero Therapeutics compare to Smith Micro Software?

Which has better valuation and earnings, SMSI or ENTO?

Do analysts prefer SMSI or ENTO?

Which has more risk and volatility, SMSI or ENTO?

Do institutionals & insiders hold more shares of SMSI or ENTO?

Is SMSI or ENTO more profitable?

Does the media prefer SMSI or ENTO?

Summary

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools